Business Context and Reporting Period
This Form 8-K Current Report was filed by BioLife Solutions, Inc. (BLFS) on March 24, 2025, covering events occurring on March 18, 2025. The filing addresses corporate governance changes, specifically the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and does not contain financial performance data.
Material Changes
The primary material change reported is the appointment of Catherine Coste to the Board of Directors, effective March 18, 2025. Key details include:
- Role: Member of the Board and Chair of the Audit Committee.
- Term: Serving until the Company's 2025 Annual Meeting of Stockholders.
- Independence: The Board determined Ms. Coste qualifies as an "independent" director under SEC and Nasdaq rules, including heightened standards for Audit Committee members.
- Background: Ms. Coste brings over 32 years of experience with Deloitte & Touche LLP, where she served as a senior partner and life sciences industry executive leader. She is a licensed Certified Public Accountant (CPA) and has previously served as Audit Committee Chair for Biomerica, Inc., Minerva Surgical, Inc., and Renalytix plc.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future performance. No new risks or contingencies were disclosed in this report. The filing confirms there are no undisclosed transactions or arrangements between Ms. Coste and the Company required to be reported under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for additional context on the appointment.
- Review the Company's 2024 Proxy Statement (filed June 5, 2024) to confirm the specific compensation structure for non-employee directors, which applies to Ms. Coste on a prorated basis.
- Confirm the date of the 2025 Annual Meeting of Stockholders to determine the exact end date of Ms. Coste's interim term.